© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
May 12, 2022
In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.
April 20, 2022
Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.
April 19, 2022
Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.
April 08, 2022
Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.
March 30, 2022
Lori Wirth, MD, provides an overview of differentiated thyroid cancer including patient presentation and disease course.